Faultory

Case file 84 · Science & Discovery

The missing pregnancy data

Drug safety, 1961: could a sedative be treated as safe without data on pregnancy?

Subject
Thalidomide and the FDA review (1961)
Reading
14 min
Evidence
5 exhibits
Reasoning
3 steps
Level
Intermediate
President Kennedy handing a pen to Senator Estes Kefauver after signing a bill, with officials around the table.
10 October 1962 President Kennedy signs the 1962 drug amendments, with Dr. Frances Oldham Kelsey among those present. Photo: Abbie Rowe · Public domain · Wikimedia Commons.
Illustrative signature. An illustrative strip of case reports over time shows a quiet interval followed by a rising count (a sketch, not data). Drawn to explain the case, not plotted from source data.

01 · The briefing

Begin with the question.

Thalidomide was a sedative that had been sold in several European countries before its American sponsor, Richardson-Merrell, applied for approval in the United States. The application was reviewed by the Food and Drug Administration, and the medical officer Frances Oldham Kelsey was the reviewer who kept asking for more data. Her oral history recalls that the company's clinical material was largely testimonials rather than well-designed studies.

The review was already contentious. A report of peripheral neuritis in long-term users led Kelsey to ask the sponsor for more information. Later in 1961, a German pediatrician, Widukind Lenz, linked the drug to a wave of birth defects in Europe. Before that link was widely understood, the narrower question in the American file was whether the drug had been shown safe for pregnant women at all.

Critics argued that the FDA was obstructing a drug already sold abroad. Kelsey's account is that the criticism faded once the question of pregnancy safety came up at a company conference and it became clear that the data were not there. This investigation separates what the record documents from what was later recalled, and asks what the evidence did and did not establish.

Frances Oldham Kelsey and President John F. Kennedy at a presentation.
Where it happened7 August 1962 Dr. Frances Oldham Kelsey receives the medal for Distinguished Federal Civilian Service from President Kennedy on 7 August 1962. Photo: Unknown author · Public domain · Wikimedia Commons.

The timeline

  1. Kelsey recalls receiving the thalidomide application for review in early September 1960, when she found deficiencies in the clinical material.

  2. Merrell holds a conference with its clinical investigators, where the question 'Is thalidomide safe in pregnancy?' is raised and, according to Kelsey, the data to answer it are not available.

  3. By November 1961, Widukind Lenz determines that thalidomide is the cause of the malformations he is seeing and finds that 50 percent of the mothers of deformed children had taken it in the first trimester.

  4. President Kennedy presents Kelsey with the medal for Distinguished Federal Civilian Service.

  5. President Kennedy signs the 1962 drug amendments, Public Law 87-781, which require substantial evidence of effectiveness and add effectiveness to the safety requirements for new drugs.

  6. The FDA publishes a feature on Kelsey's review, describing her request for further information after the neuritis report.

A researched reconstruction for learning. These reasoning steps simplify a complex record; no score can capture the full history.

02 · The evidence

What does the record show?

Read each exhibit before settling on an explanation. The source links below every exhibit lead to the record behind it.

Exhibit 01

The request after the neuritis report

The FDA's 2001 feature on Kelsey's review states that after a journal report of peripheral neuritis in patients who had taken the drug over a long period, she immediately contacted Richardson-Merrell and requested further information on this serious side effect. The feature is a retrospective agency account. It establishes what Kelsey asked for at that stage. It does not establish any link between thalidomide and birth defects, which came later from other evidence.

Source record s1web.archive.org

Exhibit 02

The pregnancy question in Kelsey's oral history

In her FDA oral history, Kelsey recalls that Merrell's application was weak, that its clinical reports were more like testimonials than well-designed studies, and that when the question of safety in pregnancy arose at Merrell's conference, the criticism of the FDA ended because the data were not there. She describes asking for case histories of use throughout pregnancy. The transcript establishes her account of the request and the gap. It is a recollection given decades later, so it shows her view of the file rather than the drug's effects.

Source record s2web.archive.org

Exhibit 03

Lenz's first-trimester finding

The same FDA feature reports that Widukind Lenz, by November 1961, determined that thalidomide was the cause of the deformities, and that 50 percent of the mothers with deformed children had taken the drug in the first trimester of pregnancy. This establishes the association Lenz reported from clinical questioning of families. It does not give a rate of harm among all women who took the drug, because the figure is a share of affected mothers.

Source record s1web.archive.org

Exhibit 04

Public and legislative context in 1981

Wallace Janssen's 1981 FDA Consumer history states that the births of thousands of deformed infants whose mothers had taken the sedative thalidomide focused public attention on pending U.S. legislation, and it ties the case to Kelsey's review. It establishes the public and legislative context. It is a historical summary written by an agency historian and does not give the number of affected children in the United States.

Source record s3fda.gov

Exhibit 05

The 1962 statute's evidence standard

Public Law 87-781, dated 10 October 1962, states its purpose to assure the safety, effectiveness and reliability of drugs. Its text refers to a lack of substantial evidence that a drug will have the effect it purports to have. This establishes the legal standard that followed the thalidomide episode. It does not mention thalidomide or pregnancy, and it does not show how the FDA applied the standard in any particular case.

Source record s4govinfo.gov

03 · Your reasoning

Follow the strongest explanation.

Choose an interpretation, then compare it with the evidence. You can revise your choice. The goal is understanding, not a perfect score.

Reasoning step 01 of 03

What exactly was missing from the 1961 application, according to the evidence?

Evidence-based explanation

Kelsey's oral history states that she asked for case histories of use throughout pregnancy, and that the data for the pregnancy-safety question were not there. The FDA's 2001 feature records her earlier request about neuritis, and her oral history says it was the neuritis that led the FDA to ask about use in pregnancy. The account is a recollection given decades later, so it is strongest on what she asked for and weakest on the exact sequence of meetings.

Weigh it against

Exhibit 01The request after the neuritis reportExhibit 02The pregnancy question in Kelsey's oral history

Reasoning step 02 of 03

How strong is the 50 percent figure as evidence of harm?

Evidence-based explanation

The 50 percent figure is a share among mothers of deformed children who had taken the drug in the first trimester. It is a strong signal that justified action, but it was drawn from clinical questioning rather than a controlled comparison, and it cannot give the chance of harm for a woman who takes the drug. Reading it as a rate for all users would overstate what the source establishes.

Weigh it against

Exhibit 03Lenz's first-trimester findingExhibit 04Public and legislative context in 1981

Reasoning step 03 of 03

What did the 1962 amendments change about the standard for approving a new drug?

Evidence-based explanation

Public Law 87-781 states its purpose as assuring the safety, effectiveness and reliability of drugs, and its text refers to a lack of substantial evidence that a drug will have its claimed effect. The change therefore added effectiveness alongside safety and set an evidence standard. The statute does not mention thalidomide, so the link to the case rests on the historical record rather than the statute's own text.

Weigh it against

Exhibit 04Public and legislative context in 1981Exhibit 05The 1962 statute's evidence standard

04 · The findings

The chain behind the outcome.

The documented core of this case is narrow. Kelsey asked the sponsor for evidence of safety in pregnancy, and according to her oral history the evidence was not available. The FDA's 2001 feature records her earlier request about a serious neuritis report, and the 1981 FDA Consumer history places the case within the public and legislative response to the births of thousands of deformed infants in Europe.

Lenz's finding is a warning sign, not a rate. By November 1961 he had linked the malformations to thalidomide, and he found that half of the mothers of deformed children had taken the drug in the first trimester. That shows an association and a window of exposure among affected families. It does not give the chance of harm for a woman who takes the drug, and it does not measure how many children were affected in the United States.

The FDA did not approve the application. Its objections rested on missing evidence of safety, not on a proven teratogenic effect, and Merrell withdrew the application in March 1962. The sources describe deficiencies and a withdrawal, not a formal refusal order. The 1962 amendments turned the standard into law: Public Law 87-781 required substantial evidence and added effectiveness to the safety requirements. The case is often told as a victory for caution, but the record supports a narrower lesson, that a regulator can withhold approval on missing evidence, and the gap in the evidence is itself the finding to examine.

Contributing causes and conditions

  1. Thalidomide was used in several countries, including for sedation and for morning sickness, before its American application was reviewed.
  2. Reports of peripheral neuritis from long-term use led the FDA reviewer to request more information from the sponsor.
  3. The sponsor's clinical material was weak and did not include case histories of use throughout pregnancy, so the pregnancy-safety gap stayed open.
  4. German clinicians, led by Lenz, linked the drug to malformations, with half of the mothers of deformed children reporting first-trimester use.
  5. Public and legislative attention to the European births carried the 1962 amendments, which required substantial evidence of effectiveness and added it to the existing safety requirements.

OutcomeThalidomide and the FDA review (1961)

Take the method with you

  1. When a safety claim rests on missing data, name the population the data must cover, here pregnant women.
  2. A case-based association can justify action without giving a rate, so keep the association and the risk for an individual separate in your reasoning.
  3. Withholding approval for missing evidence is different from proof of harm, and a decision rule should say which one applies.

You can read findings at any time. Exploring every reasoning step marks this case as complete in your notebook.

Open another investigation

The open record

Sources & further reading

Read the original record and its scope before relying on a conclusion. Source references support the exhibit summaries; Faultory’s reasoning prompts are editorial reconstructions.

  1. s1
  2. s2
  3. s3
  4. s4

Written and curated for Faultory by Yunus Emre Vurgun, with AI-assisted research and drafting. Sources and interpretations can need correction. Read our editorial standards or report an issue.

Keep investigating